Abstract:The persistence of increased excitability and spontaneous activity in injured peripheral neurons is imperative for the development and persistence of many forms of neuropathic pain. This aberrant activity involves increased activity and/or expression of voltage-gated Na + and Ca 2+ channels and hyperpolarization activated cyclic nucleotide gated (HCN) channels as well as decreased function of K + channels. Because they display limited central side effects, peripherally restricted Na + and Ca 2+ channel blockers and K + channel activators offer potential therapeutic approaches to pain management. This review outlines the current status and future therapeutic promise of peripherally acting channel modulators. Selective blockers of Na v 1.3, Na v 1.7, Na v 1.8, Ca v 3.2, and HCN2 and activators of K v 7.2 abrogate signs of neuropathic pain in animal models. Unfortunately, their performance in the clinic has been disappointing; some substances fail to meet therapeutic end points whereas others produce dose-limiting side effects. Despite this, peripheral voltage-gated cation channels retain their promise as therapeutic targets. The way forward may include (i) further structural refinement of K + channel activators such as retigabine and ASP0819 to improve selectivity and limit toxicity; use or modification of Na + channel blockers such as vixotrigine, PF-05089771, A803467, PF-01247324, VX-150 or arachnid toxins such as Tap1a; the use of Ca 2+ channel blockers such as TTA-P2, TTA-A2, Z 944, ACT709478, and CNCB-2; (ii) improving methods for assessing “pain” as opposed to nociception in rodent models; (iii) recognizing sex differences in pain etiology; (iv) tailoring of therapeutic approaches to meet the symptoms and etiology of pain in individual patients via quantitative sensory testing and other personalized medicine approaches; (v) targeting genetic and biochemical mechanisms controlling channel expression using anti-NGF antibodies such as tanezumab or re-purposed drugs such as vorinostat, a histone methyltransferase inhibitor used in the management of T-cell lymphoma, or cercosporamide a MNK 1/2 inhibitor used in treatment of rheumatoid arthritis; (vi) combination therapy using drugs that are selective for different channel types or regulatory processes; (vii) directing preclinical validation work toward the use of human or human-derived tissue samples; and (viii) application of molecular biological approaches such as clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Analgesic potential of voltage gated sodium channel modulators for the management of pain

Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception

The physiological function of different voltage-gated sodium channels in pain

Sodium Channel Inhibitors (Nav1.7, 1.8, And 1.9) For Neuropathic Pain Management

Ion Channel Genes in Painful Neuropathies

High-Voltage-Activated Calcium Channel in the Afferent Pain Pathway: an Important Target of Pain Therapies.

Selective Voltage-Gated Sodium Channel Peptide Toxins from Animal Venom: Pharmacological Probes and Analgesic Drug Development

Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain

Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?

Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain.

The Voltage-Gated Calcium Channel α2δ Subunit in Neuropathic Pain

Research Advance in Sodium Channels Involved in Neuropathic Pain

Specific Subunits of Voltage-Gated Sodium Channel Underlying the Subthreshold Membrane Potential Oscillations: Potential Therapeutic Targets for Neuropathic Pain

Recent advances in small molecule Nav 1.7 inhibitors for cancer pain management

Human pain channelopathies

Optogenetic and Chemogenic Control of Pain Signaling: Molecular Markers

Regulating excitability of peripheral afferents: emerging ion channel targets

Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230